Galderma showcased significant updates across its dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The company reinforces its leadership commitment in dermatology innovation with 22 scientific presentations, including two oral e-posters.
Nemluvio
Nemolizumab (Nemulizumab), Galderma’s treatment for prurigo nodularis and atopic dermatitis, was a key focus at AAD 2025. A new oral presentation showcases Nemluvio’s efficacy up to Week 16 across pruriginous lesion types in prurigo nodularis patients. Post-hoc analyses confirm Nemluvio provides a sustained response up to 56 weeks in atopic dermatitis patients. It benefits those with partial or no response at Week 16.
The company will present real-world data on atopic dermatitis, analysing treatment access disparities across ethnic groups. Another study will explore the link between itch severity and initiation of biologic therapy.
Restylane, Sculptra, and Relfydess.
The company continues to push boundaries in aesthetic dermatology, with new insights on its Restylane, Sculptra, and Relfydess portfolios. A study will assess Restylane, Lyft/Contour with Sculptra for restoring facial volume loss in patients undergoing medication-driven weight loss. Additionally, a comparative analysis will explore the genetic pathways influenced by Sculptra versus other biostimulators.
A study will present the first ultrasound-based comparison of Restylane Contour’s integration, support, and lifting capacity versus another hyaluronic acid filler. Another AI-enabled study will assess delayed complications associated with hyaluronic acid fillers.
The latest phase III READY-4 and phase IIIb RELAX trial data will highlight Relydes’ long-term effectiveness in reducing frown lines and crow’s feet. Previous READY trial findings show that 39 percent of patients see results on day one, and 75 percent maintain improvements for six months.
Solutions for acne and sensitive skin
Galderma is also showcasing new developments in acne and sensitive skin care. A global study will explore the link between adult acne and sensitive skin, offering valuable insights into treatment approaches. Additionally, presentations on Galderma’s CTMP™ regimen—Cleanse, Treat, Moisturise, Protect—will highlight its impact on adherence, treatment outcomes, and overall skin health.
A stronger future in dermatology
Galderma’s presentations at AAD 2025 highlight its dedication to advancing dermatology with research and innovation.
The company is expanding its portfolio with a dermal patch for acne-prone skin, a ceramide serum, a vitamin C serum, and an anti-ageing cream.